Shanghai Rightongene Biotechnology Co. Ltd. Class A
SSSE:68821721.54
CNY
-0.29
(-1.33%)
ISIN
CNE100005212
Return %
Stock
S&P 500
1Y
-25.34
14.20
3Y
-39.98
81.12
5Y
-63.55
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shang Xian Gao
- Full Time Employees
- 336
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Shanghai China
- IPO Date
- May 17, 2021
- Website
- rightongene.com
- Similar Companies
- Business
- Shanghai Rightongene Biotechnology Co., Ltd. is a Chinese biotechnology and molecular diagnostics company primarily engaged in the research, development, manufacturing, and commercialization of in vitro diagnostic reagents, medical testing instruments, and precision oncology diagnostic services. Founded in 2012 and headquartered in Shanghai, China, the company operates across major domestic medical and research markets through operating subsidiaries including Shanghai Yuanqi Biomedical Technology Co., Ltd. and Wuhan Baitai Gene Engineering Co., Ltd. The company's product and service portfolio encompasses molecular diagnostics, cytogenetics, and personalized medicine tailored for hospitals, clinical laboratories, and pharmaceutical companies. Core offerings include hematologic oncology diagnostic reagents, such as BCR-ABL P210 fusion gene quantitative detection kits, 15-gene leukemia fusion panels, AML1-ETO and PML-RARA fusion gene assay kits, Ruifulin lymphocyte receptor gene rearrangement detection kits, and 15-color full-spectrum flow cytometry Minimal Residual Disease monitoring panels; solid tumor diagnostic reagents, comprising epidermal growth factor receptor mutation detection kits for non-small cell lung cancer, KRAS and BRAF gene mutation assays for colorectal cancer, MET and HER2 testing panels, and UGT1A1 chemotherapeutic drug metabolism genotyping kits; infectious disease testing products, including nucleic acid detection assays for SARS-CoV-2, Rubella virus, Mycoplasma genitalium, Herpes simplex virus types 1 and 2, and Hepatitis B virus pre-C region mutations; automated diagnostic instruments, featuring nucleic acid extraction and purification workstations, digital PCR platforms, rapid fluorescence in situ hybridization systems, and analytical cell sorters; and comprehensive testing services, encompassing clinical tumor subtyping, minimal residual disease monitoring, translational research support, and biomarker testing for clinical drug trials. In recent developments, Shanghai Rightongene Biotechnology Co., Ltd. has expanded its precision oncology diagnostic ecosystem through strategic clinical and commercial alliances, including collaborations with AstraZeneca on the MET and HER2 precision diagnostic alliance, joint programs with Merck on standardized colorectal cancer molecular testing, and translational clinical research on diffuse large B-cell lymphoma molecular classification with Shanghai Ruijin Hospital. The company has continued to commercialize newly approved assays under National Medical Products Administration authorizations for advanced hematologic and solid tumor panels while scaling its spectral flow cytometry diagnostic offerings. Concurrently, the company underwent notable corporate governance and executive management realignments following regulatory investigations into senior leadership in late 2024, leading to the restructuring of internal compliance mechanisms, leadership transitions, and operational optimization focused on core high-value molecular diagnostic lines.